Table 1.
Notable mutations that benefit the infectivity, transmissibility and immune escape of SARS-CoV-2.
| Mutations | Locations | Representative Lineages | Functions | References |
|---|---|---|---|---|
| S13I | N-terminal domain | B.1.427 | Immune escape | [25] |
| L18F | N-terminal domain | Beta, Gamma | Immune escape | [26] |
| del69-70 | N-terminal domain | Alpha, Omicron* | Immune escape/Increase transmissibility | [27] |
| W152C | N-terminal domain | B.1.427 | Immune escape | [25] |
| K417N/T | Receptor binding domain | Beta, Gamma, Omicron | Attenuate biding affinity to ACE2/Immune escape | [28] |
| N439K | Receptor binding domain | AV.1 | Increase binding affinity to ACE2/immune escape | [29] |
| N440K | Receptor binding domain | Omicron | Increase infectivity | [30] |
| L452R | Receptor binding domain | Delta | Immune escape | [31-33] |
| Y453F | Receptor binding domain | Delta | Immune escape | [34] |
| S477G/N/R | Receptor binding domain | Omicron | Immune escape | [35] |
| E484K/Q/P | Receptor binding domain | Beta, Gamma, Delta, Eta, Lota, Kappa, Mu, Omicron | Immune escape | [31,32] |
| S494P | Receptor binding domain | Alpha | immune escape | [36,37] |
| N501Y | Receptor binding domain | Alpha, Beta, Gamma, Mu, Omicron | Increase infection and transmissibility | [7,28] |
| D614G | S1 domain-C terminal | All lineages | Increase infectivity | [22] |
| H655Y | Close to S1/S2 cleavage site | Gamma, Omicron | Immune escape | [38] |
| P681H/R | Close to S1/S2 cleavage site | Alpha, Kappa, Mu, Omicron | Increase cleavage efficiency | [10] |
Omicron is underlined to indicate multiple mutations and deletions from other variants.